Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULCGet Rating) have been given an average rating of “Moderate Buy” by the seven brokerages that are covering the company, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $30.83.

Several brokerages have recently weighed in on FULC. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Fulcrum Therapeutics in a research note on Friday, August 12th. Stifel Nicolaus reissued a “buy” rating and issued a $43.00 price target on shares of Fulcrum Therapeutics in a research note on Friday, May 27th. Finally, Credit Suisse Group decreased their price target on Fulcrum Therapeutics to $22.00 in a research note on Monday, August 15th.

Institutional Investors Weigh In On Fulcrum Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. FMR LLC boosted its position in shares of Fulcrum Therapeutics by 0.5% during the 2nd quarter. FMR LLC now owns 6,127,231 shares of the company’s stock valued at $30,023,000 after purchasing an additional 30,753 shares in the last quarter. Suvretta Capital Management LLC boosted its position in shares of Fulcrum Therapeutics by 10.0% during the 1st quarter. Suvretta Capital Management LLC now owns 2,613,412 shares of the company’s stock valued at $61,807,000 after purchasing an additional 237,841 shares in the last quarter. BlackRock Inc. boosted its position in shares of Fulcrum Therapeutics by 0.9% during the 1st quarter. BlackRock Inc. now owns 2,228,610 shares of the company’s stock valued at $52,707,000 after purchasing an additional 20,532 shares in the last quarter. Point72 Asset Management L.P. boosted its position in shares of Fulcrum Therapeutics by 511.9% during the 2nd quarter. Point72 Asset Management L.P. now owns 1,988,800 shares of the company’s stock valued at $9,745,000 after purchasing an additional 1,663,800 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. boosted its position in shares of Fulcrum Therapeutics by 45.8% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 1,720,000 shares of the company’s stock valued at $30,427,000 after purchasing an additional 540,000 shares in the last quarter. Institutional investors own 96.96% of the company’s stock.

Fulcrum Therapeutics Stock Down 1.4 %

Shares of FULC opened at $8.72 on Tuesday. Fulcrum Therapeutics has a 12-month low of $3.21 and a 12-month high of $33.10. The business has a 50-day simple moving average of $7.14 and a two-hundred day simple moving average of $9.84. The stock has a market cap of $357.60 million, a PE ratio of -3.33 and a beta of 2.48.

Fulcrum Therapeutics Company Profile

(Get Rating)

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.

Featured Articles

Analyst Recommendations for Fulcrum Therapeutics (NASDAQ:FULC)

Receive News & Ratings for Fulcrum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulcrum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.